CNBC
26 Jun 2026, 11:00 UTC · 4h ago
Estrogen patches are hard to find, and it may not be resolved any time soon
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
CNBC
26 Jun 2026, 11:00 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Prescriptions for estrogen patches increased 162% over the past two years, with total estrogen prescriptions rising 78%. — Indicates a massive structural shift in demand for hormone replacement therapies, benefiting providers and manufacturers who can scale.
+0.60Hims & Hers (Hers) reports that interest in its perimenopause and menopause program has tripled since October. — Directly positive catalyst for a publicly traded telehealth company capturing a high-growth market segment.
+0.50Three types of estradiol patches are facing shortages due to high demand and manufacturing complexity, with some suggests it could take a year to catch up. — Supply constraints limit revenue realization for manufacturers in the short term and create operational friction for healthcare providers.
-0.40Continue reading
6 related stories
Search tags
The FDA removed a 20-year-old black box warning regarding hormone replacement therapy risks last fall. — A regulatory tailwind that lowers the barrier for physician prescribing and increases patient adoption.
+0.30Which stocks this story touches
The company's menopause program interest has tripled, benefiting from a surge in demand for hormone replacement therapies.
The company is struggling to keep pace with skyrocketing demand, leading to supply shortages.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
19h ago
